Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.59 |
| ▸ | GAA | P10253 | 1/20 | 0.59 |
| ▸ | CA12 | O43570 | 2/20 | 0.54 |
| ▸ | CA1 | P00915 | 2/20 | 0.54 |
| ▸ | CA2 | P00918 | 2/20 | 0.54 |
| ▸ | CA9 | Q16790 | 2/20 | 0.54 |
| ▸ | CPB1 | P15086 | 1/20 | 0.51 |
| ▸ | KDM1A | O60341 | 2/20 | 0.48 |
| ▸ | MAOA | P21397 | 2/20 | 0.48 |
| ▸ | MAOB | P27338 | 2/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | RCOR1 | Q9UKL0 | 1/20 | 0.47 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29129479 | 0.94 | TSHR (0.54) | TSHRALDH1A1GAACA12CA1 | |
| SCHEMBL28595580 | 0.94 | TSHR (0.54) | TSHRALDH1A1GAACA12CA1 | |
| SCHEMBL5674337 | 0.93 | ALDH1A1 (0.54) | TSHRALDH1A1GAACA12CA1 | |
| SCHEMBL29385701 | 0.90 | TSHR (0.51) | TSHRALDH1A1GAACA12CA1 | |
| SCHEMBL9741141 | 0.87 | CA12 (0.54) | TSHRALDH1A1GAACA12CA1 | |
| SCHEMBL28595583 | 0.87 | TSHR (0.53) | TSHRALDH1A1GAACA12CA1 | |
| SCHEMBL19204881 | 0.86 | TSHR (0.50) | TSHRALDH1A1GAACA12CA1 | |
| SCHEMBL29017563 | 0.85 | TSHR (0.49) | TSHRALDH1A1GAACA12CA1 | |
| SCHEMBL29017564 | 0.85 | TSHR (0.49) | TSHRALDH1A1GAACA12CA1 | |
| SCHEMBL28434707 | 0.83 | ALDH1A1 (0.53) | ALDH1A1GAASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116768883-A | Pyrimido aromatic ring compounds and application thereof in medicines | 广东东阳光药业股份有限公司 | 2023-09-19 | — | — | CN | disclosed |
| CN-112996784-B | Indole derivatives and their use in medicine | 北京越之康泰生物医药科技有限公司 | 2023-05-30 | — | — | CN | disclosed |
| US-11370761-B2 | Voltage-dependent T-type calcium channel inhibitor | NIPPON CHEMIPHAR CO., LTD. (JP) | 2022-06-28 | — | — | US | disclosed |
| CN-113620960-A | Substituted pyrrolizine compounds and uses thereof | 吉利德科学公司 | 2021-11-09 | — | — | CN | disclosed |
| US-20210323930-A1 | VOLTAGE-DEPENDENT T-TYPE CALCIUM CHANNEL INHIBITOR | KINKI UNIVERSITY (JP) | 2021-10-21 | — | — | US | disclosed |
| CN-109790168-B | Substituted pyrrolizine compounds and uses thereof | 吉利德科学公司 | 2021-09-17 | — | — | CN | disclosed |
| CN-112996784-A | Indole derivatives and their use in medicine | 北京越之康泰生物医药科技有限公司 | 2021-06-18 | — | — | CN | disclosed |
| CN-108863958-B | Preparation method of 4, 7-diazaspiro [2.5] octane derivative | 南京药石科技股份有限公司 | 2020-10-27 | — | — | CN | disclosed |
| CN-106749233-B | Sulfonamide derivatives and application thereof | 中山大学 | 2020-04-21 | — | — | CN | disclosed |
| WO-2020057403-A1 | INDOLE DERIVATIVE AND MEDICAL APPLICATION THEREOF | 北京越之康泰生物医药科技有限公司 | 2020-03-26 | — | — | WO | disclosed |
| EP-3572403-A1 | VOLTAGE-DEPENDENT T-TYPE CALCIUM CHANNEL INHIBITOR | Nippon Chemiphar Co., Ltd. (JP) | 2019-11-27 | — | — | EP | disclosed |
| CN-108863958-A | A kind of preparation method of 4,7- diaza spiro [2.5] Octane derivatives | 南京药石科技股份有限公司 | 2018-11-23 | — | — | CN | disclosed |
| EP-2545051-B1 | COMPOUNDS FOR THE TREATMENT OF HEPATITIS C | BRISTOL MYERS SQUIBB CO (US) | 2017-04-19 | — | — | EP | disclosed |
| CN-104837858-A | Ketoamide immunoproteasome inhibitors | HOFFMANN LA ROCHE | 2015-08-12 | — | — | CN | disclosed |
| US-8354410-B2 | Compounds for the treatment of hepatitis C | BRISTOL-MEYERS SQUIBB COMPANY (US) | 2013-01-15 | — | — | US | disclosed |
| CN-102803204-A | Cycloalkylcarbamate benzamide aniline HDAC inhibitor compounds | GILEAD COLORADO INC | 2012-11-28 | — | — | CN | disclosed |
| US-20120059019-A1 | Compounds for the Treatment of Hepatitis C | BRISTOL-MYERS SQUIBB COMPANY | 2012-03-08 | — | — | US | disclosed |
| CN-1125051-C | Heteroaryl aminoguanidines and alkoxyguanidines and their use as protease inhibitors | DIMENSIONAL PHARM INC (US) | 2003-10-22 | — | — | CN | disclosed |
| CN-1283189-A | Heteroaryl aminoguanidines and alkoxyguanidines and their use as protease inhibitors | DIMENSIONAL PHARM INC (US) | 2001-02-07 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120059019-A1 | Compounds for the Treatment of Hepatitis C | HAVCR2, HCCS, SLC10A1 | TSHR 3992/4885ALDH1A1 239/4885GAA 162/4885 |
| US-11370761-B2 | Voltage-dependent T-type calcium channel inhibitor | CACNA1I, CACNA1G, CACNA1H | TSHR 2215/4885ALDH1A1 3666/4885GAA 4574/4885 |
| US-20210323930-A1 | VOLTAGE-DEPENDENT T-TYPE CALCIUM CHANNEL INHIBITOR | CACNA1I, CACNA1G, CACNA1H | TSHR 2215/4885ALDH1A1 3666/4885GAA 4574/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.